The Wall Street Journal
12/06/2015
Price Bomb of Gilead
The liberals demanding pharmaceutical price controls, and the Republicans warming to the idea, have moved on from their outrage over the Hepatitis C cure that debuted two years ago.
Ron Wyden of Oregon and Chuck Grassley of Iowa conducted an 18-month probe into Gilead Sciences and their drug Sovaldi to investigate the drug's high price.
After examining more than 20,000 pages of internal documents and conducting dozens of interviews with executives, the Senate Finance Committee probe determined that Gilead deliberately and rationally set a price for sofosbuvir (Sovaldi). In perhaps the most transparent look ever into pricing decisions in the modern drug business, they ultimately concluded that "Gilead's marketing, pricing and contracting strategies were focused on maximizing revenue."
Read the full article here.
Share